Actos Lawsuit News: Plaintiff's Attorney Argues That Takeda Put Profits Over People, Notes the Rottenstein Law Group

Share Article

This week the jury heard that the diabetes drug, manufactured by Takeda Pharmaceutical Co., is allegedly tied to cancer and that Takeda allegedly hid the related study results in order to be able to market the drug. The Rottenstein Law Group, which represents clients in Actos bladder cancer lawsuits, is concerned about this revelation.

DePuy ASR Hip Replacement

DePuy ASR Hip Replacement

It is too early to determine what a verdict in this first trial could mean for future cases, but surely those who believe Actos has injured them should consider pursuing a lawsuit regardless.

The nation’s first Actos trial is near its end in Los Angeles. This week the jury heard that the diabetes drug, manufactured by Takeda Pharmaceutical Co., is allegedly tied to cancer and that Takeda allegedly hid the related study results in order to be able to market the drug.* The Rottenstein Law Group, which represents clients in Actos bladder cancer lawsuits, is concerned about this revelation.

During the trial (Cooper v. Takeda Pharmaceuticals America Inc.; CGC-12-518535, California Superior Court, Los Angeles), the plaintiff’s lawyer argued that while Takeda’s internal studies showed links to bladder cancer in 2004, Takeda did not alert regulators in the United States until 2011, in order to protect a nearly $2 billion business, according to Bloomberg, which further reported that the jury could begin deliberations this week. The lawyer for plaintiff Jack Cooper asked the jury to award his client $5.3 million in damages.

“If it is true that Takeda concealed risk data to preserve profits, then it is important that the company be held accountable,” said Rochelle Rottenstein, principal of the Rottenstein Law Group. “It is crucial that all the facts come out and are considered. It is too early to determine what a verdict in this first trial could mean for future cases, but surely those who believe Actos has injured them should consider pursuing a lawsuit regardless.”

Takeda recently won approval for a new diabetes drug, Nesina, which was designed to replace Actos, for which the company lost its patent in 2011, according to Bloomberg.

The bulk of the more than 3,000 Actos cases are being handled in a federal pretrial consolidation called a “multidistrict litigation” in the Western District of Louisiana (MDL-2299). Cooper’s state court suit is not part of that MDL.

The Rottenstein Law Group has been monitoring the case and encourages people to visit the firm’s Actos lawsuits page on its website to learn more information about the drug and how to contact an Actos attorney to learn more about filing a lawsuit.

*bloomberg.com/news/2013-04-15/takeda-s-actos-diabetes-drug-tied-to-cancer-jury-is-told.html

About THE ROTTENSTEIN LAW GROUP
The Rottenstein Law Group is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices. (Attorney advertising. Prior results do not guarantee a similar outcome.)

Contact:
The Rottenstein Law Group, LLP
Rochelle Rottenstein, Esq.
321 W. 44th Street
# 804
New York NY 10036
(212) 933-9500 (office phone)
(212) 933-9980 (facsimile)
rochelle (at) rotlaw (dot) com
http://www.rotlaw.com

                            ###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Rochelle Rottenstein, Esq.
Follow us on
Visit website